Abstracts tagged "oral and rheumatoid arthritis (RA)"

Abstract Number: 10L • 2017 ACR/ARHP Annual Meeting
Upadacitinib (ABT-494) in Patients with Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Biological Dmards: A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of a Selective JAK-1 Inhibitor
Mark C. Genovese¹, Roy Fleischmann², Bernard Combe³, Stephen Hall⁴, Ying Zhang⁵, Yijie Zhou⁵, Mohamed-Eslam F. Mohamed⁶, Sebastian Meerwein⁷ and Aileen L. Pangan⁵, ¹Stanford University Medical Center, Palo Alto, CA, ²University of Texas Southwestern Medical Center at Dallas, Dallas, TX, ³Rheumatology, CHU Lapeyronie and Montpellier University, Montpellier, France, ⁴Department of Medicine, Monash University, Cabrini Health and Emeritus Research, Malvern, Australia, ⁵AbbVie Inc., North Chicago, IL, ⁶Clinical Pharmacology and Pharmacometrics, AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co, Ludwigshafen, Germany

Background/Purpose: Upadacitinib (ABT-494, UPA), an oral, selective JAK-1 inhibitor was effective in 2 ph2 trials in rheumatoid arthritis (RA) pts with inadequate response (IR)/intolerance to…
Abstract Number: 491 • 2017 ACR/ARHP Annual Meeting
Streptococcus Species Enriched in the Oral Cavity of RA Patients: A Persistent Source of Peptidoglycan-Polysaccharide Polymers Which Drive Disseminated Synovial Inflammation
Rabia Moentadj¹, Linda Rehaume², Paraic O Cuiv³, Kate Ormerod⁴, Muralidhara Maradana³, Vanessa Anne Lakis³, Mark Morrison², Philip Hugenholtz⁴, Helen Benham⁵, Kim-Anh Lê Cao⁶ and Ranjeny Thomas¹, ¹University of Queensland Diamantina Institute, Brisbane, Australia, ²The University of Queensland Diamantina Institute, Translational Research Institute, Brisbane, Australia, ³The University of Queensland Diamantina Institute, Brisbane, Australia, ⁴Australian Centre for Ecogenomics, The University of Queensland, Brisbane, Australia, ⁵The University of Queensland Faculty of Medicine, Brisbane, Australia, ⁶School of Mathematics and Statistics, Centre for Systems Genomics, The University of Melbourne, Melbourne, Australia
Background/Purpose: In Rheumatoid Arthritis (RA), genetic predisposition and environmental risk factors promote dysbiosis of oral and fecal microbiota. We hypothesized that specific microbial taxa (operational…
Abstract Number: 1046 • 2015 ACR/ARHP Annual Meeting
Previous Biologic Disease-Modifying Antirheumatic Drug (bDMARD) Exposure and Efficacy and Safety Analysis from a Phase 3 Study of Baricitinib in Patients with Rheumatoid Arthritis and an Inadequate Response to Tumor Necrosis Factor Inhibitors
Mark C. Genovese¹, Joel M. Kremer², Cynthia Kartman³, Douglas E. Schlichting³, Li Xie³, Tara Carmack⁴, William L. Macias³ and Josef S. Smolen⁵, ¹Division of Rheumatology, Stanford University Medical Center, Palo Alto, CA, ²Center for Rheumatology, Albany, NY, ³Eli Lilly and Company, Indianapolis, IN, ⁴Quintiles, Durham, NC, ⁵Department of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Baricitinib, an oral inhibitor of JAK1/JAK2, improved disease activity with an acceptable safety profile in a phase 3 study (RA-BEACON) of patients with active…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].